SG11201901928SA - Mucoadhesive microorganism - Google Patents
Mucoadhesive microorganismInfo
- Publication number
- SG11201901928SA SG11201901928SA SG11201901928SA SG11201901928SA SG11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA SG 11201901928S A SG11201901928S A SG 11201901928SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bacteria
- microorganism
- microorganisms
- pct
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title abstract 8
- 230000003232 mucoadhesive effect Effects 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 abstract 2
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 abstract 2
- 102000015728 Mucins Human genes 0.000 abstract 2
- 108010063954 Mucins Proteins 0.000 abstract 2
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 abstract 2
- 102000007641 Trefoil Factors Human genes 0.000 abstract 2
- 108010007389 Trefoil Factors Proteins 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 101150072314 thyA gene Proteins 0.000 abstract 2
- -1 CmbA Proteins 0.000 abstract 1
- 101100349538 Dictyostelium discoideum numA gene Proteins 0.000 abstract 1
- 101000889485 Homo sapiens Trefoil factor 3 Proteins 0.000 abstract 1
- 241000194035 Lactococcus lactis Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 235000014897 Streptococcus lactis Nutrition 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 230000021164 cell adhesion Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 102000055380 human TFF3 Human genes 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940051875 mucins Drugs 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394024P | 2016-09-13 | 2016-09-13 | |
| PCT/IB2017/055470 WO2018051223A1 (en) | 2016-09-13 | 2017-09-11 | Mucoadhesive microorganism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901928SA true SG11201901928SA (en) | 2019-04-29 |
Family
ID=60190901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901928SA SG11201901928SA (en) | 2016-09-13 | 2017-09-11 | Mucoadhesive microorganism |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10808014B2 (de) |
| EP (1) | EP3512872A1 (de) |
| JP (2) | JP7022743B2 (de) |
| KR (2) | KR102348734B1 (de) |
| CN (1) | CN109983028B (de) |
| AU (2) | AU2017328129B2 (de) |
| CA (1) | CA3035488A1 (de) |
| IL (1) | IL265177A (de) |
| RU (2) | RU2021135949A (de) |
| SG (1) | SG11201901928SA (de) |
| WO (1) | WO2018051223A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200077534A (ko) * | 2017-10-20 | 2020-06-30 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 이종 단백질 생성을 위한 인공 분비 펩티드 |
| CN110129220B (zh) * | 2019-04-30 | 2021-06-22 | 石河子大学 | 一种保加利亚乳杆菌bsts6-4及其应用 |
| CN115551530A (zh) * | 2019-08-27 | 2022-12-30 | 通尼克斯制药有限公司 | 经修饰的tff2多肽 |
| CA3156035A1 (en) * | 2019-09-27 | 2021-04-01 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Treatment of celiac disease |
| WO2021158376A1 (en) * | 2020-02-06 | 2021-08-12 | Codexis, Inc. | Mucin-binding fusion proteins |
| CN111690666B (zh) * | 2020-07-30 | 2023-05-05 | 江苏食品药品职业技术学院 | 一种重组thaumatin II结构基因、表达载体、生产甜蛋白的方法及应用 |
| KR102231437B1 (ko) * | 2020-09-21 | 2021-03-24 | 주식회사 보삼바이오산업 | 고병원성 조류 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물의 제조방법 및 그를 이용하여 제조한 고병원성 조류 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물 |
| CN112195210B (zh) * | 2020-10-24 | 2022-01-04 | 上海加新生物科技有限公司 | 一种透明质酸的生产方法 |
| CN112708577B (zh) * | 2020-12-31 | 2022-04-05 | 扬州大学 | 一种具有高肠道粘附力和免疫调节功能的发酵乳杆菌dali02及其应用 |
| AU2022220027A1 (en) * | 2021-02-09 | 2023-08-17 | Ernest Pharmaceuticals, Inc. | Intracellular delivery of therapeutic proteins designed to invade and autonomously lyse and methods of use thereof |
| CN113684201A (zh) * | 2021-08-27 | 2021-11-23 | 日照市畜牧兽医管理服务中心 | 基于Caco-2细胞高效诱变筛选肠道定植益生菌的育种方法 |
| CN114377117B (zh) * | 2021-12-06 | 2023-11-10 | 中国医学科学院医学生物学研究所 | 一种口服1型糖尿病疫苗及其制备方法 |
| CN115197885B (zh) * | 2022-09-13 | 2022-12-09 | 中国农业科学院北京畜牧兽医研究所 | 格氏乳球菌lgm15及菌剂和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB227835A (en) | 1924-01-15 | 1925-04-09 | Harry Odell | Improvements in feeding mechanism for embossing and other printing presses |
| US4919918A (en) | 1988-03-14 | 1990-04-24 | Spectrum Consumer Products Co., Inc. | Non-alcoholic mouthwash |
| US5972685A (en) | 1988-07-21 | 1999-10-26 | Iowa State University Research Foundation, Inc. | Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration |
| GB9126306D0 (en) | 1991-12-11 | 1992-02-12 | Unilever Plc | Mouthwash compositions |
| WO1993017117A1 (en) | 1992-02-27 | 1993-09-02 | Lynxvale Limited | Heterologous gene expression in lactococcus, and the expression products therefrom |
| US5223285A (en) | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| US5700782A (en) | 1993-05-28 | 1997-12-23 | Abbott Laboratories | Enteral nutritional product |
| AU2149495A (en) | 1995-04-11 | 1996-10-30 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface |
| US5695746A (en) | 1995-07-28 | 1997-12-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Liquid dentifrice with mouthwash fresh taste |
| US6348187B1 (en) | 1996-01-24 | 2002-02-19 | Warner-Lambert Company | Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems |
| GB9611364D0 (en) | 1996-05-31 | 1996-08-07 | Smithkline Beecham Plc | Composition |
| GB2318977B (en) | 1996-09-18 | 1999-07-21 | Erling Johansen | Compositions |
| US5869118A (en) | 1996-11-13 | 1999-02-09 | Abbott Laboratories | Gellan gum to improve physical stability of liquid nutritional products |
| US5897872A (en) | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
| US6171611B1 (en) | 1997-11-12 | 2001-01-09 | Dante J. Picciano | Iodine-containing nasal moisturizing saline and mouthwash solutions |
| US6100388A (en) | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
| WO2000018377A1 (en) | 1998-09-28 | 2000-04-06 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
| WO2000022909A2 (en) | 1998-10-19 | 2000-04-27 | Biotech Australia Pty. Limited | Systems for oral delivery |
| ATE342983T1 (de) | 1999-07-05 | 2006-11-15 | Vlaams Interuniv Inst Biotech | Bereitstellung von peptiden mit kleeblattstruktur |
| EP1383897B1 (de) | 2001-05-03 | 2006-06-28 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Selbsterhaltender lactococcus stamm |
| JP2004534075A (ja) * | 2001-06-14 | 2004-11-11 | ノボ ノルディスク アクティーゼルスカブ | Ｔｆｆダイマーペプチドによる粘膜修復 |
| JP2006503545A (ja) * | 2002-02-14 | 2006-02-02 | ラター， ウィリアム ジェイ． | 処置される宿主における切断についてのキメラ分子 |
| EP1536749A2 (de) | 2002-07-08 | 2005-06-08 | Joe S. Wilkins, Jr. | Antibakterielle formulierungen |
| WO2005090396A1 (en) * | 2004-03-23 | 2005-09-29 | N.V. Nutricia | Novel mannose-specific adhesins and their use |
| WO2006018446A2 (en) | 2004-08-20 | 2006-02-23 | Actogenix Nv | Method to improve lactococcus preservation |
| AU2006286563B2 (en) | 2005-08-30 | 2012-02-23 | Intrexon Actobiotics Nv | Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
| JP5410759B2 (ja) | 2005-11-29 | 2014-02-05 | アクトジェニックス・エヌブイ | 抗原に対する粘膜寛容の誘導 |
| WO2007143212A1 (en) | 2006-06-02 | 2007-12-13 | Ariad Gene Therapeutics, Inc. | Capecitabine combination therapy |
| CN101605900B (zh) * | 2007-01-12 | 2014-04-23 | 阿克图杰尼斯公司 | 乳球菌启动子和其用途 |
| EP2774621B1 (de) | 2007-01-25 | 2018-01-24 | Intrexon Actobiotics NV | Behandlung von Immunerkrankungen durch mukosale Abgabe von Antigenen |
| CA2689658A1 (en) * | 2007-06-20 | 2008-12-24 | Actogenix Nv | Methods and compositions for treating mucositis |
| CA2750576C (en) * | 2009-02-02 | 2019-02-26 | Willem Meindert De Vos | Novel pilus polypeptides |
| US9574169B2 (en) | 2009-04-30 | 2017-02-21 | Intrexon Actobiotics Nv | Cryoprotectants for freeze drying of lactic acid bacteria |
| RU2766157C2 (ru) | 2011-06-01 | 2022-02-08 | Интрексон Актобиотикс Н.В. | Система полицистронной экспрессии для бактерий |
| WO2012168473A2 (en) | 2011-06-09 | 2012-12-13 | Dsm Ip Assets B.V. | Fusion of bioactive molecules |
| ES2676707T3 (es) | 2011-09-23 | 2018-07-24 | Intrexon Actobiotics Nv | Bacterias gram positivas modificadas y usos de las mismas |
| RU2653757C2 (ru) | 2011-09-23 | 2018-05-14 | Интрексон Актобиотикс Н.В. | Модифицированные грамположительные бактерии и их применение |
| US20150246085A1 (en) | 2012-11-01 | 2015-09-03 | The Sydney Children's Hospital Network (Randwick & Westmead) | Genetically-Modified Probiotic for Treatment of Phenylketonuria |
| WO2016124239A1 (en) * | 2015-02-04 | 2016-08-11 | Aurealis Oy | Recombinant probiotic bacteria for use in the treatment of a skin dysfunction |
| US10905727B2 (en) | 2016-01-14 | 2021-02-02 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
| JP7016865B2 (ja) | 2016-09-02 | 2022-03-03 | イントレクソン・アクトバイオテイクス・エヌブイ | Ｉｌ－１０およびインスリンを安定的に発現する遺伝子改変された細菌 |
-
2017
- 2017-09-11 EP EP17791452.0A patent/EP3512872A1/de active Pending
- 2017-09-11 JP JP2019513897A patent/JP7022743B2/ja active Active
- 2017-09-11 SG SG11201901928SA patent/SG11201901928SA/en unknown
- 2017-09-11 CN CN201780069890.3A patent/CN109983028B/zh active Active
- 2017-09-11 RU RU2021135949A patent/RU2021135949A/ru unknown
- 2017-09-11 KR KR1020197009765A patent/KR102348734B1/ko active IP Right Grant
- 2017-09-11 WO PCT/IB2017/055470 patent/WO2018051223A1/en unknown
- 2017-09-11 KR KR1020227000226A patent/KR102469701B1/ko active IP Right Grant
- 2017-09-11 RU RU2019108553A patent/RU2762940C2/ru active
- 2017-09-11 AU AU2017328129A patent/AU2017328129B2/en active Active
- 2017-09-11 CA CA3035488A patent/CA3035488A1/en active Pending
- 2017-09-11 US US16/331,660 patent/US10808014B2/en active Active
-
2019
- 2019-03-05 IL IL265177A patent/IL265177A/en unknown
-
2020
- 2020-09-21 US US17/026,379 patent/US11384123B2/en active Active
-
2021
- 2021-04-27 AU AU2021202595A patent/AU2021202595B2/en active Active
-
2022
- 2022-02-07 JP JP2022016914A patent/JP7439148B2/ja active Active
- 2022-06-06 US US17/832,745 patent/US20230013523A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021202595B2 (en) | 2022-02-17 |
| AU2017328129B2 (en) | 2021-01-28 |
| AU2021202595A1 (en) | 2021-05-27 |
| RU2019108553A3 (de) | 2020-12-15 |
| WO2018051223A1 (en) | 2018-03-22 |
| KR20190056387A (ko) | 2019-05-24 |
| US20210070815A1 (en) | 2021-03-11 |
| KR102348734B1 (ko) | 2022-01-07 |
| RU2021135949A (ru) | 2022-04-14 |
| AU2017328129A1 (en) | 2019-04-04 |
| US20190194267A1 (en) | 2019-06-27 |
| JP7439148B2 (ja) | 2024-02-27 |
| JP2019530446A (ja) | 2019-10-24 |
| CN109983028B (zh) | 2023-10-20 |
| WO2018051223A4 (en) | 2018-05-03 |
| CN109983028A (zh) | 2019-07-05 |
| JP2022084579A (ja) | 2022-06-07 |
| IL265177A (en) | 2019-05-30 |
| KR102469701B1 (ko) | 2022-11-22 |
| RU2762940C2 (ru) | 2021-12-24 |
| US11384123B2 (en) | 2022-07-12 |
| KR20220005641A (ko) | 2022-01-13 |
| US10808014B2 (en) | 2020-10-20 |
| US20230013523A1 (en) | 2023-01-19 |
| EP3512872A1 (de) | 2019-07-24 |
| JP7022743B2 (ja) | 2022-02-18 |
| CA3035488A1 (en) | 2018-03-22 |
| RU2019108553A (ru) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901928SA (en) | Mucoadhesive microorganism | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201807188VA (en) | Modified cells for immunotherapy | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201803169WA (en) | Cellulase variants and polynucleotides encoding same | |
| SG11201806988UA (en) | Improved differentiation method | |
| SG11201901528RA (en) | Proteolytically cleavable chimeric polypeptides and methods of use thereof | |
| SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201808751SA (en) | T cell receptors | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
| SG11201906213UA (en) | Modulating expression of polypeptides via new gene switch expression systems | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201907769XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201911572YA (en) | Adenoviral vectors | |
| SG11201909087PA (en) | Perfusion medium | |
| SG11201805680SA (en) | Methods and compositions for the treatment of neurologic disease | |
| SG11201908891YA (en) | Perfusion medium | |
| SG11201810040WA (en) | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors | |
| SG11201906359SA (en) | Compositions and methods for maturation of oocytes in vitro |